Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Celgene Corporation CELG

Healthcare Drug Manufacturers - Major
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma... see more

Recent & Breaking News (NDAQ:CELG)

Kessler Topaz Meltzer & Check, LLP Announces Expanded Class Period in Securities Class Action Filed against Celgene Corporation

Business Wire May 3, 2018

Regeneron Pharmaceuticals: Sequencing Its Way to +30% Upside

Benzinga.com  May 3, 2018

The Klein Law Firm Announces a Class Action Commenced on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)

Business Wire May 2, 2018

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Solid Biosciences Inc. (SLDB) and Lead Plaintiff Deadline - May 28, 2018

GlobeNewswire May 2, 2018

DEADLINE ALERT: Brower Piven Reminds Investors of Upcoming Deadline in Class Action Lawsuit and Encourages Those Who Have Losses in Excess of $100,000 from Investment in Patterson Companies, Inc. to Contact the Firm

Business Wire May 2, 2018

The Klein Law Firm Announces a Class Action Filed on Behalf of Celgene Corporation Shareholders and a Lead Plaintiff Deadline of May 29, 2018 (CELG)

GlobeNewswire April 30, 2018

Celgene Corporation Announces Appointment of Jennifer Dudinak to Senior Vice President of Global Regulatory Affairs

Business Wire April 30, 2018

The Week Ahead In Biotech: PDUFA Dates, Clinical Trials, Merck And Pfizer Earnings On Tap

Benzinga.com  April 29, 2018

CELGENE SHAREHOLDER ALERT: CLAIMSFILER REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Celgene Corporation - CELG

PR Newswire April 27, 2018

CELG INVESTOR ALERT: The Law Offices of Vincent Wong Notifies Investors of a Class Action Involving Celgene Corporation and a Lead Plaintiff Deadline of May 29, 2018

Business Wire April 27, 2018

New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Business Wire April 24, 2018

Celgene Corporation to Announce Third Quarter 2017 Results on October 26, 2017; Will Host an Investor Webcast Event from the MSParis2017–7th Joint ECTRIMS – ACTRIMS Meeting on October 28, 2017

Business Wire October 2, 2017

Little-Known Biotech Breakthrough Could Save Millions Of Lives

PR Newswire September 11, 2017

Celgene Provides Update on the Fusion™ Clinical Program

Business Wire September 7, 2017

Celgene Corporation (Nasdaq: CELG) to Ring The Nasdaq Stock Market Opening Bell

GlobeNewswire September 6, 2017

Technical Reports on Biotech Equities -- Celgene, Dynavax Technologies, Keryx Biopharma, and Moleculin Biotech

PR Newswire September 6, 2017

Attention Biotech Investors: September Ushers In Another Slew Of PDUFA Catalysts

Benzinga.com  September 1, 2017

Celgene Corporation to Webcast at Upcoming Investor Conferences

Business Wire August 24, 2017

FDA Grants Approval of IDHIFA®, the First Oral Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH2 Mutation

Business Wire August 1, 2017

August PDUFA Dates: Biotech Investors Stay Tuned To A Month Of Plenty

Benzinga.com  August 1, 2017